Kisspeptin-10: A Literature Course

About this course

Kisspeptin-10 appears in the scientific record as a short peptide fragment derived from the product of the KISS1 gene, studied most heavily in reproductive neuroendocrinology and, more recently, in metabolic, skeletal and neurovascular model systems. This six-module course summarises what a set of published papers set out to measure, what the authors described, and where the evidence stops. It is a reading guide, not a protocol.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication, or participation in research. No dosing figures are reproduced here: the sources summarised are reviews and model-system reports, and quantitative dosing detail is outside the scope of this summary. Each module ends with a short statement of the limits of the evidence, because the boundaries of a study are as informative as its findings.

Module 1: What kisspeptin-10 is and how it has been studied

Definition and class

Kisspeptins are a family of related peptides encoded by the KISS1 gene that act as ligands at the G protein-coupled receptor KISS1R, also called GPR54, and reviews describe this ligand–receptor pair as a gatekeeper of the hypothalamic–pituitary–gonadal (HPG) axis (PMID 35837314). Kisspeptin-10 is the ten-amino-acid C-terminal fragment of that precursor family; longer forms, including kisspeptin-54, share the same C-terminal region and the same receptor, a point reiterated across reproductive and metabolic reviews (PMID 32427949).

Where the literature comes from

The published work spans several distinct traditions. Reproductive neuroendocrinology supplies the largest body, including reviews of kisspeptin control of the HPG axis (PMID 35837314) and of the relationship between kisspeptin signalling and prolactin (PMID 31847029). A metabolic literature examines kisspeptin as a link between energy balance and reproduction (PMID 32427949) and its emerging roles in metabolism more broadly (PMID 33977536). Separate strands use animal and cell models: sheep for pituitary hormone release (PMID 29549187), mice for bone cell biology (PMID 38346942) and for the anatomy of kisspeptin neuron projections (PMID 37389617), and hamsters for tissue expression mapping (PMID 36285151). A final, very different strand is analytical chemistry: a 2024 method paper investigated detection of kisspeptin-10 in urine by liquid chromatography high-resolution mass spectrometry and framed the peptide as doping-relevant (PMID 38978171).

Forms and terminology

• Kisspeptin (KISS1 product): the precursor family described as the endogenous ligand for KISS1R/GPR54 in reproductive reviews (PMID 35837314).
• Kisspeptin-10: the decapeptide C-terminal fragment named directly in the osteoclast study (PMID 38346942) and in the blood–brain barrier study (PMID 40712838).
• Kisspeptin antagonists: receptor-blocking analogues used as pharmacological tools, for example in ewes (PMID 29549187).

Limits of the evidence in Module 1

The label "kisspeptin" covers several peptide lengths and, in reviews, findings from the parent peptide and from fragments are often discussed together. Readers cannot assume that a statement about kisspeptin signalling in general was generated using kisspeptin-10 specifically unless the paper says so. Species also vary: ewes, mice and hamsters differ from one another and from humans in reproductive physiology.

Module 2: Mechanism as described in the literature

The HPG axis pathway

The mechanism most often described is receptor-level: kisspeptin binds KISS1R on gonadotropin-releasing hormone (GnRH) neurons, and reviews present this as the upstream control point for GnRH release and downstream gonadotropin secretion in the control of reproduction (PMID 35837314). Reviews of therapeutic development describe this same axis as the rationale for exploring kisspeptin-based agents in reproductive disorders (PMID 36413854).

Metabolic and pituitary interfaces

A second described interface is metabolic: reviews frame kisspeptin as a node linking energy balance to reproductive function (PMID 32427949), and separate reviews discuss kisspeptin in relation to glucose homeostasis (PMID 31869842) and to metabolism more generally (PMID 33977536). A third is pituitary: one review is devoted to the relationship between kisspeptin and prolactin (PMID 31847029), while an experimental report in ewes described stimulation of growth hormone by kisspeptin antagonists (PMID 29549187).

Non-reproductive signalling described in cells and tissues

Two recent reports describe intracellular pathways outside reproduction. In osteoclasts, researchers described kisspeptin-10 binding to Gpr54 and activating Dusp18-mediated dephosphorylation of Src, with prevention of bone loss as the organism-level readout (PMID 38346942). In a neurovascular model, the study attributed protection against HIV-1 Tat-induced blood–brain barrier dysfunction and neuroinflammation to the RhoA/ROCK pathway (PMID 40712838). Expression work in the adult hamster testis mapped kisspeptin presence in gonadal tissue rather than testing a signalling effect (PMID 36285151).

Limits of the evidence in Module 2

Mechanistic descriptions are pathway maps, not outcome predictions. A receptor interaction demonstrated in isolated osteoclasts or in a barrier model does not establish that the same pathway dominates in an intact human. Reviews also describe mechanism at a level of generality that smooths over differences between peptide lengths, routes of administration and species.

Module 3: Reported outcomes by study

The table below summarises the model, endpoint and reported result for the experimental papers in this course. Each row is drawn from the study named in the link.

Negative and descriptive findings matter

Not every result was positive. The mouse study reported that kisspeptin neuron projections to oxytocin neurons were not necessary for parturition, a negative finding that constrains how far kisspeptin circuitry can be credited with driving birth (PMID 37389617). The hamster testis paper was descriptive, documenting where the peptide is expressed rather than what happens when it is administered (PMID 36285151). The ewe study used antagonists rather than kisspeptin-10 itself and reported growth hormone stimulation with those blocking agents (PMID 29549187).

Limits of the evidence in Module 3

These are heterogeneous experiments with different species, endpoints and designs; they cannot be pooled into a single statement about "what kisspeptin-10 does." Bone and blood–brain barrier findings come from disease-specific models. None of the reported outcomes constitutes evidence of benefit in healthy people, and reviews of therapeutic avenues describe kisspeptin-based development as an area of ongoing investigation rather than settled practice (PMID 36413854).

Module 4: Kisspeptin-10 Side Effects: What Studies Report

Adverse-event reporting is the weakest part of the literature summarised in this course. The experimental papers here were designed around mechanistic and physiological endpoints — bone loss and Src signalling in one case (PMID 38346942), barrier integrity and neuroinflammation in another (PMID 40712838) — and their titles and stated aims do not centre on tolerability or a catalogue of adverse effects.

Similarly, the reviews in this set are framed around physiology and therapeutic rationale rather than safety surveillance: one reviews kisspeptin in the control of the HPG axis and reproduction (PMID 35837314), one reviews novel therapeutic avenues (PMID 36413854), and others review metabolic and prolactin relationships (PMID 33977536, PMID 31847029).

What can and cannot be said

• Within this verified source set, no adverse-event frequencies, severity grades or discontinuation rates are available to summarise.
• Absence of adverse-event reporting in a mechanistic paper is not evidence of safety; it means the question was not the study's endpoint.
• Physiological plausibility of endocrine effects follows from the axis these reviews describe — kisspeptin signalling sits upstream of gonadotropin release (PMID 35837314) and has been discussed in relation to prolactin (PMID 31847029) and glucose homeostasis (PMID 31869842) — but plausibility is not the same as documented adverse events.

Limits of the evidence in Module 4

A reader looking for a tolerability profile will not find one in these papers. Any statement about how often a specific adverse effect occurs would require controlled human trials with pre-specified safety endpoints, and no such dataset is represented in this course's source list.

Module 5: Pharmacokinetics, where data exist

Formal pharmacokinetic parameters — half-life, clearance, volume of distribution, bioavailability by route — are not reported in the verified sources gathered for this course, so none are stated here. The closest adjacent evidence is analytical rather than clinical: a 2024 method paper investigated the detection of kisspeptin-10 in urine using liquid chromatography high-resolution mass spectrometry and described the peptide as doping-relevant (PMID 38978171). That work speaks to whether the compound or its analytical signature can be identified in a biological matrix, which is a detection question rather than a disposition question.

Reviews touch on why kinetics matter for development. Discussions of novel therapeutic avenues for kisspeptin consider how peptide agents might be formulated and deployed, which is precisely the domain where kinetic properties become decisive (PMID 36413854). Reviews of the HPG axis also note the pulsatile nature of the system that kisspeptin signalling feeds into, a temporal feature relevant to any dosing science (PMID 35837314).

Limits of the evidence in Module 5

Without published kinetic parameters in this source set, nothing can be said here about duration of exposure, accumulation or route comparisons. Short peptides in general are handled differently from small molecules, but a general statement about peptides is not data about kisspeptin-10.

Module 6: Regulatory status, stated factually

Approved products

There is no marketed medicine whose active ingredient is kisspeptin-10 approved by the United States Food and Drug Administration or, to the extent reflected in this literature, by comparable regulators. Reviews describing kisspeptin-based approaches present them as investigational therapeutic avenues rather than approved therapies (PMID 36413854).

Research-use-only material

Peptides sold under "research use only" (RUO) labelling are supplied for laboratory investigation and are not authorised for human administration. RUO labelling is a regulatory category describing the intended use of the material; it is not an approval, a quality guarantee, or a signal that human safety has been evaluated.

Compounding

Under the United States Federal Food, Drug, and Cosmetic Act, a bulk drug substance may generally be used in compounding under section 503A only if it is a component of an FDA-approved drug, is the subject of an applicable USP or NF monograph, or appears on the FDA's 503A bulk drug substances list; outsourcing facilities operate under the parallel 503B framework. Substances that meet none of those criteria fall outside the compounding pathway.

Anti-doping context

Sports-science laboratories have treated kisspeptin-10 as an analyte of interest: the 2024 method study explicitly framed it as a novel doping-relevant peptide and worked on urinary detection by high-resolution mass spectrometry (PMID 38978171). Athletes subject to testing programmes are governed by the rules of their own sporting bodies.

Regulatory descriptions on this page are general information, not legal advice, and rules differ by country and can change.

Limits of the evidence in Module 6

Regulatory status is jurisdiction-specific and time-sensitive. A statement accurate at the time of writing may not describe every national framework, and the scientific literature is not a substitute for a current regulatory database.

What the studies did not test

Reading across all six modules, several questions remain unanswered by the papers cited here:

1. Long-term administration in humans. The experimental reports summarised involve cells, mice, ewes and hamsters (PMID 38346942, PMID 29549187, PMID 36285151), not long-duration human cohorts.
2. Tolerability endpoints. No paper in this set was structured as a safety study with pre-specified adverse-event collection.
3. Pharmacokinetics. No half-life or exposure parameters appear in these sources; the nearest work is a urinary detection method (PMID 38978171).
4. Performance, body composition or libido outcomes in healthy adults. These endpoints do not appear among the studies cited; the metabolic literature here is mechanistic and review-level (PMID 33977536, PMID 31869842).
5. Comparisons between kisspeptin forms. Head-to-head comparisons of kisspeptin-10 against longer forms are not represented in this source set, although reviews describe the shared receptor system (PMID 32427949).

The honest summary is that kisspeptin-10 sits in a well-described physiological system with a growing set of model-system findings and a thin clinical evidence base. Readers evaluating claims about it can usefully ask which species was studied, which endpoint was measured, and whether the paper tested administration at all or simply described where the peptide is expressed.

References

• The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction (Frontiers in Endocrinology, 2022)
• Metabolic regulation of kisspeptin - the link between energy balance and reproduction (Nature Reviews Endocrinology, 2020)
• Emerging roles for kisspeptin in metabolism (The Journal of Physiology, 2022)
• Kisspeptin and Glucose Homeostasis (Seminars in Reproductive Medicine, 2019)
• Kisspeptin and Prolactin (Seminars in Reproductive Medicine, 2019)
• Novel therapeutic avenues for kisspeptin (Current Opinion in Pharmacology, 2022)
• Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src (Nature Communications, 2024)
• Kisspeptin-10 protects against HIV-1 Tat-induced blood-brain barrier dysfunction and neuroinflammation via RhoA/ROCK pathway: Implications for HAND therapy (Neurotoxicology, 2025)
• Stimulation of growth hormone by kisspeptin antagonists in ewes (The Journal of Endocrinology, 2018)
• Kisspeptin neuron projections to oxytocin neurons are not necessary for parturition in the mouse (Brain Structure & Function, 2023)
• Expression of Kisspeptin in the Adult Hamster Testis (Development & Reproduction, 2022)
• Investigating the detection of the novel doping-relevant peptide kisspeptin-10 in urine using liquid chromatography high-resolution mass spectrometry (Biomedical Chromatography, 2024)